Publication: Using drugs to target necroptosis: dual roles in disease therapy
Authors
Wang, Zhen ; Guo, Li Min ; Zhou, Hong kang ; Qu, Hong ke ; Wang, Shu Chao ; Liu, Feng Xia ; Chen, Dan ; Huang, Ju Fang ; Xiong, Kun
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de BiologĂa Celular e HistologĂa
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-11-968
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Necroptosis is programmed necrosis, a
process which has been studied for over a decade. The
most common accepted mechanism is through the RIP1-
RIP3-MLKL axis to regulate necroptotic cell death. As a
result of previous studies on necroptosis, positive
regulation for promoting necroptosis such as HSP90
stabilization and hyperactivation of TAK1 on RIP1 is
clear. Similarly, the negative regulation of necroptosis,
such as through caspase 8, c-FLIP, CHIP, MK2, PELI1,
ABIN-1, is also clear. Therefore, the promise of
corresponding applications in treating diseases becomes
hopeful. Studies have shown that necroptosis is involved
in the development of many diseases, such as ischemic
injury diseases in various organs, neurodegenerative
diseases, infectious diseases, and cancer. Given these
results, drugs that inhibit or trigger necroptosis can be
discovered to treat diseases. In this review, we briefly
introduce up to date concepts concerning the mechanism
of necroptosis, the diseases that involve necroptosis, and
the drugs that can be applied to treat such diseases.
publication.page.subject
Citation
Histology and Histopathology, Vol.33, nÂş8, (2018)
item.page.embargo
Ir a EstadĂsticas
Este Ătem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/